(Q24810552)

English

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 July 2017

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies (English)

1 reference

Europe PubMed Central

4 July 2017

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

Francisco J Esteva

1

1 reference

Europe PubMed Central

4 July 2017

Carol D Cheli

2

1 reference

Europe PubMed Central

4 July 2017

Herbert Fritsche

3

1 reference

Europe PubMed Central

4 July 2017

Monica Fornier

4

1 reference

Europe PubMed Central

4 July 2017

Dennis Slamon

5

1 reference

Europe PubMed Central

4 July 2017

Robert P Thiel

6

1 reference

Europe PubMed Central

4 July 2017

Diana Luftner

7

1 reference

Europe PubMed Central

4 July 2017

Farooq Ghani

8

1 reference

Europe PubMed Central

4 July 2017

language of work or name

0 references

publication date

8 April 2005

1 reference

Europe PubMed Central

4 July 2017

Breast Cancer Research

1 reference

Europe PubMed Central

4 July 2017

7

1 reference

Europe PubMed Central

4 July 2017

R436-43

1 reference

Europe PubMed Central

4 July 2017

4

1 reference

Europe PubMed Central

4 July 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

7 April 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

7 April 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

7 April 2017

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

7 April 2017

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

7 April 2017

HER-2-targeted therapy: lessons learned and future directions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

28 September 2017

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

28 September 2017

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

28 September 2017

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

28 September 2017

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

28 September 2017

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

28 September 2017

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

28 September 2017

The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

28 September 2017

Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

30 May 2018

Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1186%2FBCR1020

21 January 2018

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1186%2FBCR1020

21 January 2018

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

1 reference

https://api.crossref.org/works/10.1186%2FBCR1020

21 January 2018

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1186%2FBCR1020

21 January 2018

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2FBCR1020

21 January 2018

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1186%2FBCR1020

21 January 2018

ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1175054

28 November 2018

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15987448

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

https://pubmed.ncbi.nlm.nih.gov/15987448

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15987448

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is circulating HER-2 more than just a tumor marker?

1 reference

https://pubmed.ncbi.nlm.nih.gov/15987448

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15987448

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR1020

1 reference

Europe PubMed Central

4 July 2017

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Europe PubMed Central

4 July 2017

ResearchGate publication ID

0 references

Springer Nature article ID

10.1186/bcr1020

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24810552&oldid=1833393609"